8-HYDROXYQUINOLINE RODENT STUDIES SHOW "NO EVIDENCE OF CARCINOGENICITY," HHS'
8-HYDROXYQUINOLINE RODENT STUDIES SHOW "NO EVIDENCE OF CARCINOGENICITY," HHS' Natl. Toxicology Program stated in a July 8 Federal Register notice announcing the availability of a technical report on the rodent testing. The compound is an off-white to white crystal or crystalline powder used as an analytical reagent and an antimicrobial agent in medicine, fungicides, and insecticides; as a preservative in cosmetics and tobacco; a chemical intermediate in dye synthesis; and a precipitating reagent in nuclear power plant liquid waste effluent, the notice says. NTP conducted carcinogenesis studies of 8-hydroxyquinoline, at a purity of 99%, by administering the chemical in feed to groups of 50 male and 50 female rats and mice at concentrations of 0, 1,500, or 3,000 ppm for 103 weeks. "These concentrations were selected because the chemical at higher concentrations resulted in reduced feed consumption, decreases in mean body weights, and deaths in the 15-day and 13-week studies," the notice says. Average daily doses were estimated to be 73 and 143 mg/kg for male rats, 89 and 166 mg/kg for female rats, 217 and 396 mg/kg for male mice, and 349 and 619 mg/kg for female mice. None of the animals developed cancer over two years at the concentrations of the chemical given, NTP says. Copies of the technical report -- - "Toxicology and Carcinogenesis Studies of 8-Hydroxyquinoline in F344/N Rats and B6C3Fl Mice (Feed Studies) (T.R. 276)" -- are available free of charge from the NTP Public Information Office, M.D. B2-04, P.O. Box 12233, Research Triangle Park, North Carolina 27709, 919/541-3991 or FTS: 629-3991.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth